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tion in 2006 in the following counties: Vas (6.326 inhabitants/pharmacy), Pest (5.913
inhabitants/pharmacy) and Nógrád (5.855 inhabitants/pharmacy), while the small-
est: Bács-Kiskun (4.034 inhabitants/pharmacy), Békés (4.165 inhabitants/phar-
macy) and Somogy (4.218 inhabitants/pharmacy). In 2010 Nógrád (5.123 inhabit-
ants/pharmacy), Vas (4.632 inhabitants/pharmacy) and Pest (4.424 inhabitants/
pharmacy) counties had the largest catchment population, while Bács-Kiskun
(3.222 inhabitants/pharmacy), Békés (3.458 inhabitants/pharmacy) and Csongrád
(3.441 inhabitants/pharmacy) had the lowest. CONCLUSIONS: Between 2007-2010,
as the consequence of the increasing number of pharmacies, the average catch-
ment population of pharmacies decreased significantly. The regional differences
among counties did not change during the study period and remained high.
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OBJECTIVES: The value of a drug can be expressed as cost needed to increase a unit
of health. However, summarizing the economic value of a molecule with multiple
indications is a complex process. The COVET study was conducted to facilitate a
comprehensive economic evaluation of adalimumab across all approved
indications. METHODS: An algorithm was developed to estimate the total eco-
nomic value of adalimumab. This value was calculated as the sum of the incre-
mental cost-utility ratios for treating rheumatoid arthritis, psoriatic arthritis, an-
kylosing spondylitis, Crohn’s disease, and psoriasis from a Italian National Health
Care (NHC) perspective. Estimates of the cost per quality-adjusted life year (QALY)
gained by using adalimumab instead of standard therapy were derived from pre-
viously developed economic models. The sum was weighted by the prevalence of
each of the diseases considered. Through a systematic literature review, the cost
per QALY gained by using other anti-TNF drugs was extrapolated. Subsequently, a
Boston matrix was developed to establish the relationship between demand and
health supply. A one-way sensitivity analysis (SA) performed to assess the robust-
ness of the results. RESULTS: The total economic value of adalimumab in Italy
amounted to €34,750 per QALY. The sensitivity analysis showed a cost per QALY
gained ranging between €27,447 and €40,412. The analysis of the Boston matrix
indicated that, with the exception of psoriasis, the cost per QALY gained by using
adalimumab instead of standard therapy was below the common WTP threshold.
In comparison with innovative molecules, the total economic value of adalimumab
was positive and sustainable. CONCLUSIONS: This study provides an estimate of
the cost-effectiveness of adalimumab across all approved indications that is below
the threshold value for health care interventions. The results should encourage
decision makers to facilitate patient access to this cost-effective treatment. They
may also promote research to develop innovative molecules that are even more
cost-effective.
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ANALYSIS OF HOW PAYERS INCORPORATE HEALTH ECONOMIC ANALYSES
INTO COVERAGE AND HTA DECISIONS FOR PERSONALIZED MEDICINE
DIAGNOSTICS
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OBJECTIVES: As treatments trend towards personalized medicine for conditions
with certain genetic expressions, new opportunities exist for diagnostic tests to
change the standard of care and demonstrate positive economic impact to payers.
A systematic review of the role of economic evaluation to the coverage and pay-
ment of novel diagnostics has not yet been performed. The authors undertook this
analysis to examine what evidence exists to document the use of health economic
rationale and modeling to impact reimbursement and market access outcomes for
diagnostics. METHODS: A systematic review of published literature related to the
reimbursement and health technology assessment of diagnostics was conducted.
In addition, published coverage policies and HTAs in the US, UK, and Germany
related to personalized medicine diagnostics commercialized within the last de-
cade were reviewed. Policies and HTAs were graded to document the level of im-
pact economics played to decision-outcomes, if reported. Where specific refer-
ences were not made, a review of the citations referenced was conducted to see if
economic papers or models were included within their decision-framework.
RESULTS: Most published personalized medicine diagnostic coverage policies and
HTAs reference both clinical and economic evidence, though clinical data is prior-
itized. Of the policies analyzed, national HTA groups that reviewed novel diagnos-
tics or products with companion diagnostics, were most explicit in their consider-
ation of clinical and economic data. US payers were less likely to explicitly
reference economic data. CONCLUSIONS: As treatments are becoming more and
more dependent on companion diagnostic tests to influence treatment of disease
in a variety of subgroups, the processes by which diagnostics are approved, cov-
ered, and reimbursed will become more scrutinized. More standardized and trans-
parent incorporation of economic rationale and modeling into payer coverage,
payment, and HTA evaluation processes would clarify expectations and help com-
panies plan for HEOR activities.
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OBJECTIVES: With the formation of Clinical Commissioning Groups (CCGs) GP
Practices will come together to commission services for their local populations.
However, freedoms to be delegated from the Clinical Commissioning board may
mean that considerable ‘command and control’ will still be exerted from the cen-
tre. Secondary and primary research was undertaken to gain insight into how
devolved locality based commissioning is likely to impact on access to medicines.
METHODS: We reviewed 35 first wave CCGs in terms of population coverage, fi-
nancial stability and current Primary care Trust (PCT) activities in relation to Prac-
tice based commissioning. We then interviewed 5 NHS Experts to assess whether
these CCGs would be allowed the aspirational freedoms referred to in the 2012
Health and Social Care Act- in particular prescribing freedoms formerly under the
guidance of PCTs. Various information sources were used Care Quality Commis-
sion, Audit Commission, and Health Select Committee reports to support the in-
terpretation of the findings. RESULTS: The selected CCGs represented an homoge-
neous group of practices in that they had previously demonstrated financial
stewardship and collaborative working with their ‘host’ PCTs. Many CCGs had been
devolved the Commissioning budget by their PCTs and were routinely involved in
setting up medicines management protocols with their provider hospitals. Almost
half of the CCGs had coterminous medicines management contracts shared with
their PCTs. NHS experts raised issues around corporate and clinical governance
and how practices would fundamentally want to take on the devolved financial
responsibilities.CONCLUSIONS:The NHS reforms mean that £60 Billion of the total
health care budget will be under the control of CCGs. PCTs and Strategic Health
Authorities will be abolished and with a watered down role for NICE postcode
variation may be rife; access to medicines will continue to be fraught with many
layers of decision making and further delays.
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OBJECTIVES: Active domestic pharmacovigilance programs are necessary as ad-
verse drug reaction (ADR) data from other countries may overlook safety patterns
in local populations. The success of any surveillance system relies upon active
participation of reporters. The objective of this study was to describe pharmacist
reporting of suspected ADRs in Qatar to inform policy recommendations to the
Supreme Council of Health. METHODS: A 27-item survey was developed following
comprehensive literature review of relevant published research. Questions encom-
passed broad domains including: pharmacist knowledge of and experiences in
reporting suspected ADRs; attitudes towards health professional pharmacovigi-
lance roles; perceived barriers and facilitators to reporting; and recommendations
for improvements in this process. The web-based survey was formatted for elec-
tronic delivery and response for self-administration in English or Arabic by a con-
venience sample of over 500 Qatar pharmacists. RESULTS: The survey remained
open for two months between April 30 and June 30, 2011. Of the 142 (25%) total
responses, 116 (81.6%) surveys were completed beyond demographic data and in-
cluded information about prior suspected ADR reporting experiences. Knowledge
of ADR terminology and reporting purpose among the 116 (20%) responding phar-
macists was high, but only 34 (30%) had ever made a suspected ADR report in Qatar.
Most respondents expressed positive attitudes towards pharmacist roles in phar-
macovigilance activities, but inability to recognize a potential ADR or subsequently
access a reporting form were perceived barriers, with enhanced training and effi-
ciency in report submission corresponding identified facilitators to future partici-
pation. Hospital pharmacists were 7 times more likely than ambulatory-care based
pharmacists to have reported a suspected ADR in Qatar. CONCLUSIONS: Pharma-
cists in Qatar are willing to engage in pharmacovigilance activities if supported by
increased training and transparency in the reporting process. A national infra-
structure with capacity to collect and manage suspected ADR reports and promote
patient and medication safety is exigent.
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THE EARLY BENEFIT ASSESSMENT OF NEW PHARMACEUTICALS IN GERMANY
(“AMNOG”): A STRUCTURED SURVEY ANALYSIS ONE YEAR AFTER ENACTMENT
Stoeckel F1, Neubauer AS2
1University of Bayreuth, Bayreuth, Germany, 2IfG Institute for Health Economics, München,
Germany
OBJECTIVES: In January 2011, the act for restructuring the pharmaceutical market
(“AMNOG”) was introduced in Germany. We analyzed the effects one year after
AMNOG’s implementation in an empirical study. The research focused on survey-
ing affected stakeholders, systematically summarizing their experiences, and
identifying topics of controversy. METHODS: Stakeholders were defined based on
statements during the AMNOG legislation: Payors, Pharmaceutical Industry, Na-
tional Regulatory Bodies, Scientific Experts, Patients, Care Providers, Politicians,
Pharmacies and External Service Providers. The benefit assessement process was
structured into 6 topics: Market Launch, Early Benefit Assessment, Price Negotia-
tions, Arbitration Procedure, Cost-Benefit Analysis and Process. 45 experts partic-
ipated in the structured survey (26% response rate), which consisted of closed
questions supplemented by optional open-ended questions (total 47 items). De-
scriptive statistical and dissimilarity analyses were performed. RESULTS: Between
the 9 stakeholder groups, several items were highly controversial: negotiation po-
sition of statutory health insurances (“GKV-Spitzenverband”) in rebate level nego-
tiations (distance index L21.17), use of European price reference in the arbitration
process (L21.08) and several others such as transparency of the benefit assess-
ment process (L20.95). Different response profiles were observed between stake-
holders but they yielded relatively low dissimilarities on cost-benefit assessment.
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Overall, the topic areas “Market Launch”, “Price Negotiations” and “Process” were
most controversial. Regarding stakeholder groups, those experts belonging to
Pharmaceutical industry displayed the largest differences to those of the Payor
group. 16 experts answered the open-ended question about “costs of dossier pro-
cess” ranging between €100,000 and €500,000 per drug assessed. CONCLUSIONS:
We performed a structured survey analysis with experts to assess the new German
benefit assessement process based on their one year experience. Several topics and
items of high controversy between the affected stakeholders were identified. How-
ever, due to the limited quantitative outcomes experience with the AMNOG pro-
cess to date future research is needed to increase our knowledge about the legis-
lation.
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OBJECTIVES: The use of generic medicines, which can generate large savings to
health care budgets, should be supported by incentives on both the supply side and
the demand side. Pharmacists’ remuneration can influence the choice of the dis-
pensed drug. The aim of this study is to provide an overview of different pharma-
cist remuneration systems for generic medicines in Europe, with a view to explor-
ing how pharmacist remuneration systems can contribute to generic medicine
dispensing. METHODS: Data were obtained from a literature review, a Master the-
sis in Pharmaceutical Care at the University of Leuven and a mailing sent to all
members of the Pharmaceutical Group of the European Union with a request for
information about the local remuneration systems of community pharmacists and
the possible existence of reports on discounting practices. RESULTS: Pharmacists’
remuneration in most European countries consists of the combination of a fixed fee
per item and a certain percentage of the acquisition cost or the delivery price of the
medicines. This percentage component can be fixed, regressive or capped for very
high-cost medicines and acts as a disincentive for dispensing generic medicine.
Information on discounting for generic medicines, which is common practice in
several European countries, tends to be confidential. Data showed that discounts
varied from 10% to 70% of the wholesale selling price. CONCLUSIONS: Pharmacists
should not be financially penalized for dispensing generic medicines. Therefore,
their remuneration should move towards a fee-for-performance remuneration in-
stead of a price-dependent reimbursement which is currently used in many Euro-
pean countries. Such a fee-for-performance remuneration system provides a stim-
ulus for generic medicines dispensing as pharmacists are not penalized for
dispensing generic medicines. More and more European countries are moving to-
wards such a remuneration system. Pharmacists’ remuneration systems also need
to account for the loss of income to pharmacists from prohibiting discounting
practices.
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OBJECTIVES: After the Pharmaceutical Market Restructuring Act (AMNOG) took
effect in 2010, almost all pharmaceutical companies consider how to position
themselves differently in health care related value chains. The law offers new
options for the pharmaceutical and medical devices industry to reorganize their
business models in order to become an active and equal partner in integrated care
contracts with insurance companies. This paper examines key success factors for
collaborating with other stakeholders. METHODS: Due to the distinctiveness and
topicality of integrated care contracts, four cases of selective contracting between
the industry and insurance companies were scrutinized. On this basis, experts of
all parties (pharmaceutical industry, health care providers, insurance companies,
and management companies) were interviewed. RESULTS: Whereas insurance
companies and health care providers, as well as health care providers and the
pharmaceutical industry have gained experience in cooperating with each other
(e.g., in clinical trials), fears of contacts between insurance companies and the
pharmaceutical industry still exist. They need to be abolished by establishing ca-
pable structures and a bi-lateral willingness to cooperate. Pivotal elements of se-
lective contracting can be allocated to four segments, namely markets (exceed
certain thresholds such as number of patients enrolled), products (targeting of
“real” care-gaps and physicians’ relief), management (distribution of tasks, evalu-
ation concepts), and financial mechanisms (gain-sharing as means to achieve rev-
enue and profitability). First experiences in Germany have proofed technology-
based contracts to be suitable for inexperienced companies to start with. The level
of complexity of selective contracts and the timely component are often
underestimated. CONCLUSIONS: Pilot projects are now being implemented into
practice which underpins their topicality and the importance of adequate evalua-
tion. Their success depends on the inclusion of relevant partners and the intelli-
gent combination of the stakeholders’ various strengths. The objective is to de-
velop concepts which are applicable outside of Germany on international markets.
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OBJECTIVES: In early 2012, there were a number of serious events in the implant
area. A recent example are the defective breast implants of the French company
Poly Implant Prothese. The second incident concerns ‘metal on metal’ (MoM) hip
implants. These events raised public awareness and started a scientific discussion
in academia and politics on safety issues and monitoring medical devices. Appar-
ently, there is a big lack in the surveillance of medical devices. Therefore, the
objective of this work is to detect existing implant registries in the European Union.
METHODS: A systematic review of the literature was carried out to identify differ-
ent types of implant registries in the European Union Member States (EU MS). The
systematic search for implant registries was performed in the databases PubMed,
Medline, CRD York. All results up to April 2012 were considered. RESULTS: Ninety-
nine registries in the EU MS for different types of implants were identified. As
demonstrated, most registries exist in the field of cardiac implants and arthro-
plasty (34 and 30 within Europe). The distribution of implant registries showed
variation in the different EU MS. For a lot of implant categories, none or very few
registries could be identified. Some countries run more registries than others (UK
15, Portugal 1). CONCLUSIONS: The results show that there is only a limited num-
ber of reviews on registries and a centralized monitoring system in the EU MS is
missing. Our results reveal a lack of transparency concerning number, aim, struc-
ture and quality of registries. This is crucial, as registries work as an early warning
systems for identifying and notifying patients at risk. [The research is supported by
the German Federal Ministry of Education and Research (BMBF), project grant No.
01EX1013B as part of the Centre of Excellence for Medical Technology].
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OBJECTIVES: Transparency Directive (TD) (89/105/EEC) aims to foster the transpar-
ency of measures regulating the pricing and reimbursement decisions of pharma-
ceuticals in European Union Member States. TD establishes a number of funda-
mental principles including strict timelines for the pricing and reimbursement
(P&R) process. Our study focuses on the implementation of the Transparency Di-
rective in Hungary with special focus on time-limits for P&R decisions. METHODS:
We analyzed official decisions in 103 P&R submissions (positive cases with deci-
sions only) made by the National Health Insurance Fund Administration (NHIFA)
between 2004 and 2010. Most of the cases belonged to pharmaceuticals with new
active ingredients and without reimbursement at the time of submission. We ex-
cluded generic drugs and cases without P&R decision from the analysis. In order to
determine the market access time we calculated the time period between the
registration date of the drug by the European Medicines Agency (EMA) or by the
National Institute of Pharmacy (NIP) and the P&R decision. RESULTS: The average
time period from registration to P&R decision was 721 days (min: 46 days, max: 2696
days); from registration to P&R submission was 481 days (min: 1 days, max: 2581
days), from P&R submission to P&R decision was 214 days (min: 7 days, max: 990
days). Hungarian patients get access later to those medicines with centralized EMA
registration compared with medicines with national registration procedure by NIP
(average elapsed time from registration to positive decision was 827 days by EMA,
513 days by NIP). CONCLUSIONS: Periods needed for decisions are generally in
accordance with the 9090 days recommendation of the TD. There is a positive
change in pricing and reimbursement process in Hungary; decision procedure was
shorter in 2010 than it was in 2004. Hungarian patients get new, better medicines
later if the registration was done by EMA.
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OBJECTIVES:Drug development productivity has decreased over the past 10 years.
The objectives are to a) better describe the reasons for discontinuations and b) help
define the scale of the issue around discontinuing products and additional indica-
tions for reasons related to an anticipated lack of pricing and reimbursement
flexibility. METHODS: A restricted and confidential survey to four pharmaceutical
companies on their discontinued projects for lead and follow-on indications during
the period 2005-2009. Reasons for discontinuation distinguished two major cate-
gories, ‘technical’ (including failure to meet safety or efficacy targets) and ‘com-
mercial’ reasons. RESULTS: The four companies reported a total of 1,053 projects
which had been active during the period 2005-2009. Of those, 51% were discontin-
ued (n541) by the end of 2009; 332 were lead indications and 209 were follow-on
indications. About 72% of discontinuations for lead indications were for technical
reasons. The pattern for follow-on indications is more complex. Technical reasons
triggered a smaller proportion of discontinuations, presumably because many
were addressed with the lead indication. However, a greater percentage of the
discontinuations were after Phases II and III, implying higher costs to this point.
Portfolio prioritisations and exiting the disease area accounted for 20% of discon-
tinued projects. CONCLUSIONS: The results for lead indications reinforce previous
results about the growing importance of non-technical i.e. commercial reasons as
drivers for project discontinuations, around 20-25% in our sample. However, our
results show for the first time an analysis for follow-on indications and where no
comparison to previous literature is possible.
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